Dr Eric Rose - Chief Medical Officer Mesoblast June 30th webcast 2022
" Let me go back though to GvHD. To say we are not excited about this would be the understatement I think of the century. There are drugs approved recently for chronic GvHD with now two companies that have achieved more than a billion dollar valuation with that indication. We think we are going to be right in that range. This is a whole new class of theraputics, there is no off the shelf stem cell, or any cell product as far as I know aside from drug transfusions that is approved by FDA for theraputic use. The company stands at the precipice of a breakthrough in this regard for a class of therapeutics that I think will have wide use in multiple diseases, and we think it will be valued for that as well."
Dr Silviu Itescu - CEO Mesoblast Sep 30th webcast 2022
" In particular the only drug that has been approved to date for SrGvHD is Ruxolitinib. It was approved on the basis of a single open arm study, when it subsequently did a randomised control trial it was required to do in a post approval commitment, there was no survival benefit in Sr GvHD. Independent investigators more recently published a significant survival benefit with remestemcel in children with the highest risk of mortality where survival in the controls was in the order of 10%, and survival in remestemcel treated children was in the order of 64%. "
CHF FDA RMAT meeting - estimated end of Feb 2023
CLPB pivotal USA trial commence - expected April - June 2023
Remestemcel PDUFA date - estimated by June 2023
CHF partnership announcement - estimated after the RMAT meeting
ARDS trial announced - estimated H2 2023
Ryoncil phase 4 in adults - estimated H2 2023
2022 was the year of the popcorn, now it's main event time !
- Forums
- ASX - By Stock
- MSB
- 2023 The Final Countdown
2023 The Final Countdown
- There are more pages in this discussion • 3,403 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
93.0¢ |
Change
0.015(1.64%) |
Mkt cap ! $1.061B |
Open | High | Low | Value | Volume |
92.5¢ | 95.0¢ | 89.0¢ | $7.902M | 8.522M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 2945 | 92.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
93.0¢ | 40422 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 2945 | 0.925 |
21 | 78815 | 0.920 |
7 | 186474 | 0.915 |
5 | 59510 | 0.910 |
4 | 173134 | 0.905 |
Price($) | Vol. | No. |
---|---|---|
0.930 | 40422 | 4 |
0.935 | 55000 | 2 |
0.940 | 61500 | 3 |
0.945 | 68142 | 7 |
0.950 | 512886 | 20 |
Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
Last
93.0¢ |
  |
Change
0.015 ( 2.54 %) |
|||
Open | High | Low | Volume | ||
92.0¢ | 95.0¢ | 89.5¢ | 2254102 | ||
Last updated 15.59pm 26/04/2024 ? |
Featured News
MSB (ASX) Chart |